 |
 |
GEO help: Mouse over screen elements for information. |
|
| Status |
Public on Feb 28, 2023 |
| Title |
Xeno-free cultured Mesenchymal Stromal Cells release Extracellular Vesicles with a “therapeutic” miRNA cargo ameliorating cartilage inflammation in vitro |
| Organism |
Homo sapiens |
| Experiment type |
Non-coding RNA profiling by array
|
| Summary |
Mesenchymal Stromal Cells (MSCs)-derived Extracellular Vesicles (EVs) emerged as an innovative strategy for the treatment of osteoarthritis (OA). Biological activity of EVs is generally driven by their cargo, which might be influenced by microenvironment. Therefore, pre-conditioning strategies, including modifications in culture conditions or oxygen tension could directly impact on MSCs paracrine activity. Methods: A xeno-free supplement (XFS) was used for isolation and expansion of MSCs and compared to conventional fetal bovine serum (FBS) culture. Bone Marrow-derived MSCs (BMSCs) were pre-conditioned under normoxia (20% O2) or under hypoxia (1% O2) and EVs production was evaluated. Anti-OA activity was evaluated by using an in vitro inflammatory model. miRNA content was also explored, to select putative miRNA that could be involved in a biological function. Results: Modulation of IL-6, IL-8 and COX-2 was evaluated on hACs simultaneously treated with IL-1α and BMSC-derived EVs. FBS-sEVs exerted a blunt inhibitory effect, while a strong anti-inflammatory outcome was achieved by XFS-sEVs. Interestingly, in both cases hypoxia pre-conditioning allowed to increase EVs effectiveness. Analysis of miRNA content showed the upregulation in XFS-hBMSC-derived EVs of miRNA known to have a chondroprotective role, such as let-7b-5p, miR-17, miR-145, miR-21-5p, miR-214-3p, miR-30b-5p, miR-30c-5p. Activated pathways and target genes were investigated in silico and most of the upregulated miRNAs were found to be involved in TGF-beta and Wnt signalling pathways, by targeting genes related to cartilage homeostasis. Conclusions: XFS medium was found to be suitable for isolation and expansion of MSCs, secreting EVs with a therapeutic cargo. The application of cells cultured exclusively in XFS overcomes issues of safety associated with serum-containing media and makes ready-to-use clinical therapies more accessible.
|
| |
|
| Overall design |
Samples from two different primary cultures were analyzed, in 4 different conditions. Samples from 1 to 4 are treatments, samples from 5 to 8 are controls
|
| Web link |
https://www.thno.org/v13p1470.htm
|
| |
|
| Contributor(s) |
Palamà ME, Coco S, Chiorino G, Gentili C |
| Citation(s) |
37056573 |
| |
| Submission date |
Jul 22, 2022 |
| Last update date |
May 30, 2023 |
| Contact name |
simona coco |
| E-mail(s) |
[email protected], [email protected]
|
| Phone |
+390105558316
|
| Organization name |
IRCCS Ospedale Policlinico San Martino
|
| Lab |
Lung Cancer Unit
|
| Street address |
L.go R. Benzi, 10
|
| City |
Genova |
| ZIP/Postal code |
16132 |
| Country |
Italy |
| |
|
| Platforms (1) |
| GPL21576 |
Agilent-070156 Human_miRNA_V21.0_Microarray 046064 (Probe Name version) |
|
| Samples (8)
|
|
| Relations |
| BioProject |
PRJNA861290 |
| Supplementary file |
Size |
Download |
File type/resource |
| GSE209585_RAW.tar |
22.8 Mb |
(http)(custom) |
TAR (of TXT) |
| Processed data included within Sample table |
|
|
|
|
 |
Less...
More...